An article in the April 15th issue of the Journal of Experimental Pharmacology titled “Experimental Drugs for Panic Disorder: An Updated Systematic Review” has devoted a significant section to the discussion of Nobilis Therapeutics’ approach to the treatment of PTSD. The authors found our preliminary clinical data intriguing. Here is what they wrote: “differently from other NMDA receptor blockers such as ketamine, the xenon mechanism of action on the glycine site of the NMDA receptor68 does not produce psychotomimetic effects, thereby making it particularly suitable for translation to clinical psychiatric settings”
This sort of esteemed recognition is yet another attestation of the promise of our approach to the treatment of PTSD and other psychiatric disorders.
